CRISPR Therapeutics AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Net Income	-366.25	-153.61	-650.18	377.66	-348.87	Upgrade
Depreciation & Amortization	19.26	19.84	24.17	17.95	9.18	Upgrade
Asset Writedown & Restructuring Costs	-	2.5	-	-	-	Upgrade
Stock-Based Compensation	86.57	81.03	97.95	102.39	66.02	Upgrade
Other Operating Activities	-38.62	-16.55	12.47	14.11	1.86	Upgrade
Change in Accounts Receivable	175	-200	0.31	-0.16	-0.05	Upgrade
Change in Accounts Payable	-27.28	-20.25	5.16	37.51	25.75	Upgrade
Change in Unearned Revenue	-1.95	5.79	-1.01	-0.78	1.38	Upgrade
Change in Other Net Operating Assets	10.5	20.87	15.39	-9.71	6.36	Upgrade
Operating Cash Flow	-142.77	-260.38	-495.74	538.97	-238.37	Upgrade
Capital Expenditures	-1.9	-9.47	-37.19	-81.71	-18.36	Upgrade
Sale (Purchase) of Intangibles	-	-2.5	-	-	-	Upgrade
Investment in Securities	-278.58	386.62	-221.47	-953.73	-522.81	Upgrade
Investing Cash Flow	-280.48	374.65	-258.66	-1,035	-541.17	Upgrade
Issuance of Common Stock	331.98	62.66	38.59	250.95	1,016	Upgrade
Financing Cash Flow	331.98	62.66	38.59	250.95	1,016	Upgrade
Foreign Exchange Rate Adjustments	-0.02	0.07	-0.08	-0.01	0.04	Upgrade
Miscellaneous Cash Flow Adjustments	-	-0	-	-	-	Upgrade
Net Cash Flow	-91.29	177.01	-715.88	-245.52	236.66	Upgrade
Free Cash Flow	-144.68	-269.85	-532.93	457.27	-256.72	Upgrade
Free Cash Flow Margin	-387.72%	-72.69%	-44484.89%	49.98%	-35705.70%	Upgrade
Free Cash Flow Per Share	-1.71	-3.41	-6.85	5.69	-3.89	Upgrade
Levered Free Cash Flow	-29.27	-238.97	-337.58	284.82	-112.91	Upgrade
Unlevered Free Cash Flow	-29.27	-238.97	-337.58	284.82	-112.91	Upgrade
Change in Net Working Capital	-158.41	188.78	1.78	-12.73	-51.77	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.